Webb15 maj 2013 · The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate cancer (CRPC). CRPC is defined by prostate-specific antigen (PSA) or radiographic progression in the context of castrate levels of testosterone. [1] CRPC patients may or may not have … Webb25 maj 2024 · Today's standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists (e.g., leuprolide), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone.
The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise …
Webb3 juni 2024 · Androgen deprivation therapy (ADT) has been the standard of care for metastatic hormone-sensitivity prostate cancer (mHSPC). However, the effects of ADT on mHSPC vary substantially; some patients show early resistance while the others show long-term effects [1, 2].Consequently, research into the mechanism of early resistance … Webb13 apr. 2024 · The use of metastasis-directed radiotherapy plus hormone therapy improved progression-free survival (PFS) compared with hormone therpy alone in patients with … homo language of origin
Design, synthesis and biological evaluation of fluorinated
Webbför 2 dagar sedan · Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with … WebbHormone therapy may be used in several ways to treat hormone-sensitive prostate cancer, including: Early-stage prostate cancer with an intermediate or high risk of recurrence. … Webb1 apr. 2024 · Take Home Message We discovered that rare tumor cells in primary prostate cancer possess genomic features of castration-resistant prostate cancer. This … homolactic fermentation中文